Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses AI and experimental biology to discover new treatments for diseases. The company has a technology platform called ...
Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...
Recursion Pharmaceuticals hopes to use AI to accelerate drug discovery in the healthcare industry. its ambitious plans are still unproven, and the business has no approved products of its own. Nvidia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results